CLRB: Gunggung dhuwit awis saben saham cellectar.com

Lambang korporat lan logo Cellectar Biosciences (CLRB)

Cellectar Biosciences develops oncology drugs, generating revenue through the supply of radiopharmaceuticals to specialized medical centers. The cash per share metric demonstrates current liquidity, with the value of the metric standing at 2.46. The firm's success is based on the precision of isotope delivery in the treatment of Waldenström macroglobulinemia. Strong patent protection of phospholipid technologies creates a significant barrier for third-party players.

CLRB: Dhuwit awis saben saham Cellectar Biosciences Inc 04.07.2022 - 20.11.2026

Rincian analitis perusahaan Cellectar Biosciences

- rega pasar lan target rega analis:
- rincian posisi dhuwit lan arus kas:
Ringkesan analisis perusahaan:CLRB, Cellectar Corp
Produk asli cellectar.com

Cash per share determines the portion of liquid assets attributable to a single security to assess the company's intrinsic value. This metric allows an investor to evaluate the business's margin of safety and the risk of capital dilution. The trend in cash per share helps determine an entry point, minimizing losses during volatility. For Cellectar Biosciences (CLRB), this resource is critical during the commercialization of Iopofosine. The brand's high authority in hematology makes liquidity the guarantee for a successful drug launch.